Cargando…

Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls

Infections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mustafa, S. Shahzad, Shah, Deep, Bress, Jonathan, Jamshed, Saad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422465/ https://www.ncbi.nlm.nih.gov/pubmed/30303441 http://dx.doi.org/10.1080/21645515.2018.1534516

Ejemplares similares

1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)
por: Sun, Hsin-Yun, et al.
Publicado: (2018)

Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study
por: Bahuaud, Mathilde, et al.
Publicado: (2017)

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines
por: Hadjipanayis, Adamos, et al.
Publicado: (2016)

2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13
por: Syrogiannopoulos, George A, et al.
Publicado: (2019)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Dhere, Rajeev, et al.
Publicado: (2022)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients
por: Mülling, Nils, et al.
Publicado: (2023)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden
por: Galanis, Ilias, et al.
Publicado: (2016)

A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

Introduction of multi-dose PCV 13 vaccine in Benin: from the decision to vaccinators experience
por: Abdoulaye Alfa, Daleb, et al.
Publicado: (2020)

Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1
por: Kim, Hyunjung, et al.
Publicado: (2022)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Gomez, Jorge A., et al.
Publicado: (2022)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
por: Krishnan, Amrita, et al.
Publicado: (2023)

How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
por: Wouters, Ine, et al.
Publicado: (2020)

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
por: Dirmesropian, S, et al.
Publicado: (2015)

A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines
por: Bandrick, Meggan, et al.
Publicado: (2022)

Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia
por: Roca, Anna, et al.
Publicado: (2015)

Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR)
por: Abu Seir, Rania, et al.
Publicado: (2018)

Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced
por: Chang, Qiuzhi, et al.
Publicado: (2015)

Understanding vaccine hesitancy with PCV13 in children: Results of a survey in Shanghai, China
por: Ni, Yi-hong, et al.
Publicado: (2023)

Field efficacy of Porcilis® PCV M Hyo versus a licensed commercially available vaccine and placebo in the prevention of PRDC in pigs on a French farm: a randomized controlled trial
por: Pagot, Eric, et al.
Publicado: (2017)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
por: van der Linden, Mark, et al.
Publicado: (2016)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 2015
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

Antibiotic Prescription Rates in Children <24 Months Old Following PCV7/PCV13 Sequential Implementation
por: Dagan, Ron, et al.
Publicado: (2017)

Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge
por: Seo, Hwi Won, et al.
Publicado: (2014)

Characterization of a PCV2d-2 isolate by experimental infection of pigs
por: Palya, Vilmos, et al.
Publicado: (2018)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

2710. Novel Analytical Models for Pneumococcal Multiplex Opsonophagocytosis Assay Results from a Healthy Older Adult Population Vaccinated with PCV13
por: LaFon, David, et al.
Publicado: (2019)

Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
por: van der Linden, Mark, et al.
Publicado: (2015)

The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination
por: Slotved, Hans-Christian, et al.
Publicado: (2016)

PCV13 vaccination impact: A multicenter study of pneumonia in 10 pediatric hospitals in Argentina
por: Gentile, Angela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5np8317r744l0gi18b9o0v3pi9